Jan 30 (Reuters) - MITHRA PHARMACEUTICALS SA MITRA.BR :
* MITHRA ANNOUNCES POSITIVE TOP-LINE RESULTS OF ESTELLE® PHASE III ORAL CONTRACEPTIVE STUDY IN U.S/CANADA
* MITHRA ANNOUNCES POSITIVE TOP-LINE RESULTS OF ESTELLE® PHASE III ORAL CONTRACEPTIVE STUDY IN U.S/CANADA
* KEY SECONDARY ENDPOINTS ACHIEVED, INCLUDING EXCELLENT BLEEDING PROFILE, CYCLE CONTROL, QUALITY OF LIFE AND SAFETY AND TOLERABILITY
* PRIMARY EFFICACY ENDPOINT INDICATES EXCELLENT CONTRACEPTIVE EFFICACY, WITH A PEARL INDEX (PI) OF 2.41(1) PER 100 WOMEN, IN LINE WITH EXPECTATIONS
* DATA IN LINE WITH PREVIOUSLY ANNOUNCED PHASE III TRIAL IN EU / RUSSIA
* FILING WITH U.S. AND EU REGULATORY AGENCIES ANTICIPATED BY YEAR END LIÈGE, BELGIUM, 30 JANUARY 2019